Latest news with #EYPT
Business Insider
29-05-2025
- Business
- Business Insider
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report) today and set a price target of $26.00. The company's shares closed today at $7.04. Confident Investing Starts Here: Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verastem, and Apellis Pharmaceuticals. According to TipRanks, Suvannavejh has an average return of -9.0% and a 37.69% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $31.57 average price target, a 348.44% upside from current levels. In a report released today, Scotiabank also reiterated a Buy rating on the stock with a $18.00 price target. Based on EyePoint Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $24.45 million and a GAAP net loss of $45.2 million. In comparison, last year the company earned a revenue of $11.68 million and had a GAAP net loss of $29.28 million Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYPT in relation to earlier this year. Earlier this month, Karen Zaderej, a Director at EYPT bought 10,000.00 shares for a total of $59,000.00.
Washington Post
07-05-2025
- Business
- Washington Post
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
WATERTOWN, Mass. — WATERTOWN, Mass. — EyePoint Pharmaceuticals (EYPT) on Wednesday reported a loss of $45.2 million in its first quarter. The Watertown, Massachusetts-based company said it had a loss of 65 cents per share.
